Skip to main content

Table 2 Annual cost-of-illness (Euros, millions) of hypertension and the proportion of costs attributable to MetS; 2008 and 2020.

From: Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

 

Annual costs

 

Drug1

Physician2

CVD3

Type 2 diabetes4

Total

2008

Germany

     

   With MetS†

628

1,952

5,265

16,582

24,427

   Without MetS‡

407

1,264

1,703

1,967

5,341

Spain

     

   With MetS

116

126

699

968

1,909

   Without MetS

397

432

1,256

597

2,682

Italy

     

   With MetS

258

330

817

3,472

4,877

   Without MetS

958

1,222

1,599

2,178

5,957

2020

Germany

     

   With MetS†

901

2,820

8,026

27,208

38,955

   Without MetS‡

270

817

1,124

1,600

3,811

Spain

     

   With MetS

301

333

1,952

2,743

5,329

   Without MetS

384

412

1,240

816

2,852

Italy

     

   With MetS

629

813

2,117

8,964

12,523

   Without MetS

877

1,109

1,500

2,701

6,187

  1. CVD-cardiovascular disease.
  2. † hypertension patients with MetS, ‡ hypertension patients without MetS.
  3. 1Drug costs relate to antihypertensive treatments only, 2physician costs relate to visits to the clinic as a result of hypertension for check-ups and assessment of antihypertensive medication, 3CVD costs relate to ambulatory and hospitalisation costs for the management of each event, 4type 2 diabetes costs relate to the management of each patients and the costs of non-CVD related complications.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us